WATERS CORP /DE/ News
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by life science, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
see moreWATERS CORP /DE/ Market News
17 Mar at 14:51
Waters (WAT) Down 11% After BD Deal: What's Next!!
- Waters shares dropped sharply after closing its acquisition of BD’s diagnostics business, as investors weigh elevated leverage, integration risk and softer short-term guidance against durable demand from PFAS testing, GLP‑1 therapeutics and biologics.
10 Mar at 14:51
Waters Falls After BD Deal, Q4 Beat, Weak Guide
Waters Corporation reported a solid Q4 2025 but sank after issuing FY2026 guidance that disappointed investors. The close of the $17.5B BD biosciences & diagnostics acquisition amplifies long-term opportunity while raising near-term integration and margin risks investors must monitor.
03 Mar at 14:52
Waters Stock Slips After BD Integration and Q4 Beat
Waters Corp. reported solid Q4 results and closed its acquisition of BD’s biosciences/diagnostics unit, but integration uncertainty and near-term execution risks weighed on WAT shares. Analysts remain mixed-to-positive as investors watch synergy progress, guidance cadence, and diagnostics revenue ramp.
24 Feb at 15:09
Waters (WAT) Slumps After BD Spin-Off Integration.
Waters Corp reported a solid Q4 beat but issued conservative 2026 guidance after completing the BD Biosciences & Diagnostics spin-off merger. The deal adds roughly $3B in revenue but pressures margins and raised investor concerns about near-term integration risk, driving recent WAT underperformance.
17 Feb at 14:53
Waters (WAT) Q4 Beat, BD Deal Sparks Guidance Dip.
Waters reported a Q4 earnings beat driven by recurring revenue, but its 2026 guidance—reflecting the addition of BD’s Biosciences & Diagnostic unit—triggered a sharp stock decline as integration costs and a near-term margin reset weighed on sentiment.
10 Feb at 14:54
WAT Drops After Guidance; BD Merger Nears Close
Waters Corporation (WAT) cleared shareholder approval for a major BD biosciences acquisition and is set to close the deal imminently. Strong Q4 results were offset by guidance that signaled near-term margin pressure and integration complexity, prompting heightened volatility and a meaningful share-price decline. This article synthesizes the concrete events shaping WAT this week and what investors should watch next.